Examkin

Soru

Zorluk: Çok zorPharmacologic Interventions

A 74-year-old man with an 8-year history of Parkinson disease is brought to the clinic by his daughter because he has been experiencing distressing visual hallucinations over the past three weeks. He frequently sees strangers standing in his living room, which causes him significant anxiety. His motor symptoms, including bradykinesia and rigidity, are currently well controlled. He has no fever, dysuria, or recent illnesses. A urinalysis and basic metabolic panel performed in the clinic are unremarkable. His current daily medication regimen includes carbidopa-levodopa, ropinirole, selegiline, and trihexyphenidyl. Arrange the following pharmacological interventions in the correct sequential order of implementation for the stepwise management of this patient's psychosis, proceeding from the first step to the final step if symptoms remain refractory.

  1. 1Discontinue trihexyphenidyl
  2. 2Discontinue selegiline
  3. 3Discontinue ropinirole
  4. 4Reduce the dosage of carbidopa-levodopa
  5. 5Initiate pimavanserin

Cevap

The correct sequence is: 1) Discontinue trihexyphenidyl, 2) Discontinue selegiline, 3) Discontinue ropinirole, 4) Reduce the dosage of carbidopa-levodopa, 5) Initiate pimavanserin.
The standard protocol for managing Parkinson disease psychosis involves a stepwise reduction of medications. After ruling out secondary causes, the regimen is simplified by discontinuing adjunctive therapies in the following order: anticholinergics (trihexyphenidyl), amantadine, MAO-B inhibitors (selegiline), COMT inhibitors, and dopamine agonists (ropinirole). If symptoms persist, the levodopa dose is reduced. Only if these measures fail to resolve distressing hallucinations should an atypical antipsychotic like pimavanserin be initiated.

Adım Adım Çözüm

1
Exclude secondary causes of delirium and psychosis.
The absence of fever and normal laboratory findings rule out common metabolic or infectious etiologies, pointing to Parkinson disease psychosis.
Infections, metabolic derangements, and other acute medical issues must be ruled out before attributing psychosis to the disease process or its treatments.
2
Identify the most likely offending agents in the patient's regimen and begin systematic deprescribing.
Trihexyphenidyl (an anticholinergic) is discontinued first.
Anticholinergics have the highest propensity to cause confusion and hallucinations in older adults while offering the least benefit for advanced motor symptoms.
3
Continue withdrawing adjunctive Parkinson medications sequentially based on their risk-to-benefit profile.
Selegiline is stopped next, followed by ropinirole.
MAO-B inhibitors and dopamine agonists contribute to psychosis. They are withdrawn before carbidopa-levodopa because carbidopa-levodopa provides superior motor symptom control.
4
Adjust the primary motor symptom medication if hallucinations persist.
The carbidopa-levodopa dosage is reduced.
The goal is to find the lowest effective dose that controls motor symptoms without triggering severe hallucinations.
5
Add targeted pharmacotherapy for refractory psychosis as the final step.
Pimavanserin is initiated.
Atypical antipsychotics are reserved for patients whose psychosis remains distressing despite optimal simplification of the Parkinson regimen to carbidopa-levodopa monotherapy.

Anahtar Kavram

Stepwise management of Parkinson disease psychosis requires systematic deprescribing of adjunctive medications before reducing carbidopa-levodopa or adding an antipsychotic.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru